ITP About

For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

 

 

DOPTELET IS THE ONLY ORAL TPO-RA WITHOUT FOOD-TYPE RESTRICTIONS1

As an oral tablet, DOPTELET offers ease of administration for your patients

  • DOPTELET is taken with food
    • No calcium or other food restrictions
  • DOPTELET does not require additional liver-function monitoring
    • There was no significant hepatotoxicity seen in clinical trials with DOPTELET
  • No office visit for DOPTELET administration required

After initiating therapy with DOPTELET, assess platelet counts weekly until a stable platelet count of ≥50×109/L has been achieved, and then obtain platelet counts monthly thereafter. Obtain platelet counts weekly for at least 4 weeks following discontinuation of DOPTELET.

Learn more about dosing, titration, and monitoring >

TPO-RA=thrombopoietin receptor agonist.

 

 

DESIGNED TO WORK WITH THE BODY TO INCREASE PLATELET COUNTS THROUGH ORAL DOSING1

DOPTELET helps patients produce more of their own platelets

 

DOPTELET MOA

 

 

Doptelet Efficacy
DOPTELET Efficacy

Discover how DOPTELET increased platelet counts in the clinical trial.1

SEE THE DATA

 

Reference:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2019.